Abstract
To explore a possible new treatment for human ovarian cancer, we studied the effects of sodium valproate on the growth of the HO8910 human cell line. HO8910 cells were cultured in vitro and treated with different concentrations of sodium valproate. Cell proliferation, cell cycling, and apoptosis were measured by flow cytometry, cell morphology under a microscope, and expression levels of WWOX and P27 by Western blotting and RT-PCR. Tumor xenografts were established to determine in vivo effects of sodium valproate. Our results showed that cell proliferation was decreased with increasing concentration of sodium valproate, with features of cytoplasmic retraction and floating cells. Moreover, cell cycle analysis revealed a higher apoptosis rate and G0/ G1 phase in the sodium valproate experimental group than in the control group. In addition, protein expression levels of WWOX and P27 were elevated. Importantly, sodium valproate decreased in vivo xenograft tumor burden and up-regulated WWOX and P27 expression in nude mice. In conclusion, sodium valproate might play a role in inhibition and control of ovarian cancer cell line HO8910 by inhibiting cell proliferation, interfering with the cell cycle and promoting apoptosis, so that it may be effective in the clinical treatment of ovarian cancer.
Highlights
Sodium valproate, as a member of the short chain fatty acids family, is a broad-spectrum anti-epileptic drug that has been extensively used in clinical practices
Sodium valproate might play a role in inhibition and control of ovarian cancer cell line HO8910 by inhibiting cell proliferation, interfering with the cell cycle and promoting apoptosis, so that it may be effective in the clinical treatment of ovarian cancer
A gradual decrease in cell proliferation was observed with the gradual increase of sodium valproate concentration within the experimental groups
Summary
As a member of the short chain fatty acids family, is a broad-spectrum anti-epileptic drug that has been extensively used in clinical practices. It is a histone deacetylase inhibitor, which suppresses the activity of histone deacetylating (Tryfon et al, 2009). We hypothesized that sodium valproate is a remarkable drug and could be used as a new treatment for tumors In this present study, we selected human ovarian cancer cell line HO8910 as an experimental cell model and the effects of sodium valproate has been investigated on its proliferation, cell cycle, and apoptosis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
